Nisa Investment Advisors
AEGR

Nisa Investment Advisors’s Aegerion Pharmaceuticals AEGR Stock Holding History

Nisa Investment Advisors’s Portfolio AEGR Stock Details AEGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-1,300
Closed -$5K – 1897
2016
Q1 		$5K Buy
+1,300
New +$8.05K ﹤0.01% 1843

Other funds holding AEGR

SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
JG
Jefferies Group New York $12B AUM 6.2% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Nisa Investment Advisors's AEGR Position: Q2 2016 in Review

Nisa Investment Advisors sold out of Aegerion Pharmaceuticals (AEGR) in Q2 2016, closing a stake of 1,300 shares — an estimated $5K sold.

Nisa Investment Advisors first reported a position in AEGR in Q1 2016 and held it in 1 quarter. The position peaked at $5K in Q1 2016. 71 funds tracked by Wall St. Rank hold AEGR as of Q2 2016.

  • Nisa Investment Advisors reported no remaining Aegerion Pharmaceuticals position as of Q2 2016 after selling out during the quarter.
  • Nisa Investment Advisors sold 1,300 Aegerion Pharmaceuticals shares in Q2 2016, an estimated $5K.
  • Nisa Investment Advisors first reported a position in Aegerion Pharmaceuticals in Q1 2016 and held it in 1 quarter.
  • Nisa Investment Advisors's Aegerion Pharmaceuticals position peaked at $5K in Q1 2016.
  • 71 funds tracked by Wall St. Rank held Aegerion Pharmaceuticals as of Q2 2016.

Based on Nisa Investment Advisors's 13F filing for Q2 2016, filed 15 Jul 2016.